388870 — Pharos IBio Co Income Statement
0.000.00%
Last trade - 00:00- KR₩147bn
- KR₩125bn
Annual income statement for Pharos IBio Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final |
| Revenue | |||
| Total Revenue | 57 | 300 | 0 |
| Cost of Revenue | |||
| Gross Profit | 30.3 | 130 | 0 |
| Selling / General / Administrative Expenses | |||
| Research And Development | |||
| Depreciation and Amortization | |||
| Total Operating Expenses | 8,463 | 10,919 | 10,117 |
| Operating Profit | -8,406 | -10,619 | -10,117 |
| Gain / Loss on Sale of Assets | |||
| Total Net Non Operating Interest Income / Expense | |||
| Other Net Non Operating Costs | |||
| Net Income Before Taxes | -31,471 | -17,062 | -8,858 |
| Provision for Income Taxes | |||
| Net Income After Taxes | -31,471 | -17,062 | -8,858 |
| Net Income Before Extraordinary Items | |||
| Net Income | -31,471 | -17,062 | -8,858 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||
| Income Available to Common Shareholders Including Extraordinary Items | |||
| Diluted Net Income | -31,471 | -17,062 | -8,858 |
| Diluted Weighted Average Shares | |||
| Basic EPS Including Extraordinary Items | |||
| Diluted EPS Including Extraordinary Items | |||
| Diluted EPS Excluding Extraordinary Items | |||
| Normalised Income Before Taxes | |||
| Normalised Income After Taxes | |||
| Normalised Income Available to Common Shareholders | |||
| Diluted Normalised EPS | -2,436 | -1,323 | -729 |
| Dividends per Share |